By
Latest Stories
Don’t miss our hot and upcoming stories
Can BigHat and Lilly’s AI-Driven Antibody Partnership Redefine the Future of Biologics? A Two-Program Deal Aims to Accelerate Precision Therapeutics
Key Insights AI-Driven Discovery: BigHat’s Milliner™ Platform Sets New StandardsAt the core of this collaboration…
Could Proprio’s FDA-Cleared AI Platform Redefine Surgical Precision for 1,000+ Spine Centers Globally?
Key Highlights for Executives and Innovators First-Ever FDA Clearance for Real-Time Intraoperative MeasurementProprio’s Paradigm platform…
What Could Tempus and Boehringer Ingelheim’s Multi-Year AI Collaboration Mean for the Future of Cancer Drug Development?
Key Takeaways for Executives and Industry Leaders Tempus expands AI reach with a leading pharma…
What Does the Tempus–Verastem CDx Collaboration Mean for the Future of AI-Driven Precision Oncology and FDA Approvals?
Key Highlights: FDA milestone: a new era for targeted LGSOC therapiesTempus AI and Verastem Oncology…